We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

May 14, 2021

The Role of DiGA in your Go-to-Market strategy for Germany

Announcements/News
Meaghan Schedel
&

As more and more Digital Therapeutics (DTx) are developed, we are often asked: what are the most scalable and sustainable routes to market? The right commercialization model is a key component of success in this rapidly growing space. However, whether you choose a pharma partnership or another popular distribution channel, success is likely to depend on physician awareness of your DTx and their willingness to prescribe it. A direct-to-consumer approach is one way around this, but it too has its own advantages and disadvantages.

Germany’s DiGA, also known as Digital Health Applications or Digitale Gesundheitsanwendungen in German, and similar DTx review platforms (like the mhealth pyramid in Belgium) have the potential to play a key role in not only providing a path to reimbursement for DTx, but also for increasing provider awareness and trust in digital therapies. Apps that are approved for the DiGA database become reimbursable under the German statutory health insurance, making them prescribable to approximately 72.8 million people, 87.7% of the German population.


Facts and Figures: Approvals, pricing, and more 


Approvals 


Since the launch of the DiGA in 2019 as part of Germany’s initiative to increase the digitization of healthcare, the German Federal Institute for Drugs and Medical Devices (BfArM) has received a total of 72 DiGA submissions (updated: May 12th, 2021). So far 15 of these submissions have been approved and added to the DiGA Directory, 3 were denied, 30 were withdrawn, and 24 are still under review. The DiGA’s fast-tracked review process is designed to provide a rapid review of applications guaranteeing a positive or negative designation within three months or less. 


CE-marked medical devices are eligible to apply for the DiGA database so long as

1) They are a medical device of risk class I or IIA;

2) Their main function is based on digital technologies;

3) The medical purpose is achieved through the apps main digital functions;

4) The DiGA detects, monitors, treats or alleviates a disease or compensation of injuries or disabilities;

5) And finally, the DiGA must be used only by the patient or by the patient and physician in combination. 


Application process and review  


Once the application is submitted, DiGA applicants are assessed based on criteria such as data security, user friendliness, and interoperability. All DiGA must also be able to demonstrate a “positive healthcare effect” during the application process or following a 1-2 year trial phase in order to receive final admission into the database. 


A Positive Healthcare Effect


With only 15 approved applications to date, most new submissions will have to demonstrate the benefits of their app as compared to the “standard of care.” However, as the database becomes more crowded and DiGA approved applications become part of the new standard of care, applicants may be required to demonstrate how their app holds up to the competition. In these cases it will become increasingly important for apps to clearly define how their USP differs from that of an already approved DiGA with a similar value proposition. Price becomes a determining factor in a situation where two or more DiGA approved apps are determined to be no different from one another. In this case the physician may be required to prescribe the more cost-efficient option. 


Pricing 


Kalmeda is currently the least expensive app on the database at 116,97 Euros and Elevida is the most expensive at  743,75 Euros. The prescription length for these apps and most others is 90 days. With only a few apps on the database so far, it will be interesting to see how prices change as the marketplace becomes more crowded. Brian Dolan at Exits & Outcomes is tracking the latest additions to the DiGA as well as temporarily added products that may later be removed by the BfArM if they don’t receive final approval. 

Current DiGA Apps 


Approved applications cover a variety of conditions such as cancer, multiple sclerosis, and after care for stroke victims. However, many of the 15 approved apps address mental health and behavioral change. Julia Hagen, Director Regulatory & Politics at the Health Innovation Hub (hih) in Berlin, commented for MobiHealthNews, sharing that the initial focus on mental health applications is likely due to the vast number of available apps and evidence showing effectiveness in this space. She further stated: “There are also applications from completely different areas. Looking at the ongoing discussion and applications that are in the pipeline, we will soon see many other DiGA for various indications.”


Approved Apps 

Invirto - enables people with agoraphobia, panic disorder, or social phobia to receive home treatment for their anxiety disorder. 


Velibra - a web-based program for patients with generalized anxiety disorder, panic disorder with or without agoraphobia, or social anxiety disorder.  


Mindable - aims to treat adults 18 and over who suffer from the symptoms of agoraphobia and / or panic disorder. 


Kalmeda - a behavioral therapy for adults suffering from chronic ringing in the ears. 


Somnio - a digital application for the treatment of problems falling asleep and staying asleep (insomnia). 


ViViRA - a digital application for the treatment of back, knee, and hip pain. 


Zanadio - aims to help users reduce their weight by changing their exercise, nutrition, and other behavioral habits.


Elevida - designed for adults with multiple sclerosis who also have fatigue. 


M-sense Migraine - offers a comprehensive digital treatment program for migraine patients.  


Rehappy - supports aftercare for stroke patients. 


Selfapy - offers people with depression an individual online course based on evidence-based theories and techniques of cognitive behavioral therapy. 


deprexis - an interactive online-based self-help program that provides therapy support for adult patients with depression and depressive moods. 


CANKADO - a web and app based digital application that supports breast cancer patients.  


Mika - designed to support the alleviation of psychological and psychosomatic consequences of cancer diagnosis and therapy. 


Vorv!da - designed for adult patients with harmful alcohol consumption or alcohol dependence.

Physician Awareness and Trust 

It is also yet to be seen how strongly physicians will value DiGA approval and if this will increase their willingness to prescribe digital therapies to patients. So far approved DiGA apps have not seen a large increase in prescriptions as a result of their DiGA designation. In a study of 51 general practitioners conducted between April and May of 2020 and published by the Deutsches Ärzteblatt, an official journal of the German Medical Association and the National Association of Statutory Health Insurance Physician, 63% of practitioners polled described their willingness to prescribe DiGA as low or mostly low and 37% of practitioners reported their willingness as high or rather high. Our HealthXL insights show physicians are also concerned they won’t be able to answer technical questions about the apps and that it may take significant time to educate patients. As is the case for all emerging digital therapeutics, more education will be needed to increase patient and physician awareness of these new technologies and how they can be beneficial. 


However, a DiGA designation may provide a stamp of approval that increases both provider trust and awareness. Unlike a drug, a DTx may continue to change and evolve once it's on the market. For example, a DTx that uses a machine learning algorithm will continue to adapt as more user information becomes available. While this is likely positive for the app and ultimately for the patient, the potential that there may be changes to the DTx that the physician is not aware of can decrease the chance that a physician will prescribe the application. 


The DiGA has the potential to provide a sense of security and act as a time saver for physicians who want confirmation the app hasn’t undergone any significant changes without having to re-research the product before writing each prescription. The DiGA requires apps to report any “significant change.” According to criteria outlined by the BfArM this would not include something like an update to the design of a DiGA, but it would include changes to information published in the directory (such as price), changes to the safety or quality of the device, any changes to the application’s ability to meet DiGA requirements, changes to data protection, and any changes to the proof of positive healthcare effects. This requirement for DiGA to self-report changes or otherwise risk being removed from the database, may help build provider trust in the list of applications available on the database. 


The DiGA database and others like it could be an extremely valuable tool for physician education and awareness. While the early stages haven’t shown a large uptake in prescriptions, it is likely that as DTx continue to grow in range, capability, and popularity, patients will soon be asking their physicians about these alternative treatments and physicians will need a trusted source to consult. 


As this tide begins to turn, it is likely DiGA status will be a crucial component of success in the German market as well as other European markets that are following Germany’s lead. In addition to Belgium’s mhealth pyramid, we are also seeing mhealth and electronic EHR initiatives out of France, Norway, and Italy. The COVID-19 pandemic demanded innovation and acceptance of digital therapies and virtual care. Following the pandemic, we expect to see continued growth in these areas across Europe and the world. 


To learn more about other routes to market check out our “Best routes to market” meeting on May 31st featuring Louis Payet and Todd Greenwood.

Sources: 


https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Broschueren/200629_BMG_Das_deutsche_Gesundheitssystem_EN.pdf


https://www.bfarm.de/EN/MedicalDevices/DiGA/_node.html


https://www.bfarm.de/SharedDocs/Downloads/EN/MedicalDevices/DiGA_Guide.pdf?__blob=publicationFile&v=2 (p. 26 & 83) 


https://www.healthcareitnews.com/news/emea/european-digital-health-revolution-wake-covid-19 


https://www.mobihealthnews.com/news/emea/germany-approves-new-digital-mental-health-app-prescription 


https://www.digitalhealthglobal.com/italy-eyes-digital-therapeutics/



https://www.aerzteblatt.de/archiv/217790/Digitale-Gesundheitsanwendungen-Die-Akzeptanz-steigern 


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: DTx last mile delivery: HCPs and Patient adoption (Part 2)

3rd February @ 10:45AM EDT

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: The Regulation of SaMD in the US

14th February @ 10:45AM EDT

Join us in this US-focused Masterclass led by Clay Anselmo and Bernhard Kappe, As they walk us through the regulation of SaMD in the US. Apply now to secure your place.

Featuring
Bernhard Kappe
Bernhard Kappe
Founder & CEO, Orthogonal
Clay Anselmo
Clay Anselmo
VP Quality Assurance and Regulatory Affairs, ENvizion
Featuring
Bernhard Kappe
Bernhard Kappe
Founder & CEO, Orthogonal
Clay Anselmo
Clay Anselmo
VP Quality Assurance and Regulatory Affairs, ENvizion
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx - Pharma partnerships

15th February @ 10:45AM EDT

Join us as we deep dive into DTx-Pharma partnerships, with a focus on how to monetize DTx within the traditional pharmaceutical business model. Apply now to connect with peers and hear from thought leaders in this space.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Mansa Shroff
Mansa Shroff
Head of Partnerships at WKD.SMRT
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Mansa Shroff
Mansa Shroff
Head of Partnerships at WKD.SMRT
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Webinar: DTx commercialisation models - Pharma Partnerships & D2C route

17th February @ 10:00AM EDT

Last month, we did a deep dive on the Employer route to market for DTx products. Join us this month as we look into other potential go-to-market strategies for Digital Therapeutics. Apply now to hear valuable insights from thought leaders in this space.

Featuring
Pierre Leurent
Pierre Leurent
CEO, Voluntis
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee
Featuring
Pierre Leurent
Pierre Leurent
CEO, Voluntis
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Masterclass: Clinical Trials Design for Digital Health products

31st January @ 10:45AM EDT

Join us in this Masterclass led by Click Therapeutics, as we discuss Clinical Trials Design for Digital Health Products. Our Masterclass sessions are the perfect opportunity to hear from thought leaders in the space and share your own thoughts and experiences.

Featuring
Shaheen Lakhan
Shaheen Lakhan
Chief Medical Officer , Click Therapeutics
Featuring
Shaheen Lakhan
Shaheen Lakhan
Chief Medical Officer , Click Therapeutics
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Digital tech for Trial Recruitment and Retention

2nd February @ 10:45AM EDT

Join our Digital Health Meeting led by Laura Gunn from Pharmstars as we discuss digital tech for Trial Recruitment and Retention. This is the perfect opportunity to connect with peers and meet new people working in this space.

Featuring
Laura Gunn
Laura Gunn
Managing Director at PharmStars
George Platings
George Platings
Market Development Specialist at uMotif
Featuring
Laura Gunn
Laura Gunn
Managing Director at PharmStars
George Platings
George Platings
Market Development Specialist at uMotif
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: DTx last mile delivery: HCPs and Patient adoption (Part 2)

3rd February @ 10:45AM EDT

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

Digital Health Solutions with the greatest impact in cancer patients' lives

8th February @ 10:45AM EDT

How can Digital Health improve cancer patients’ lives? Are you working in this industry? Keep reading, this meeting is for you. Join us as we discuss current Digital Health products in oncology and the unmet/gaps need to be addressed.

Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.